Prostate Precision: Unveiling the Theranostic Evidence

Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. Among men, the disease ranks second only to lung cancer in terms of cancer mortality.

To date most of the evidence for theranostic treatments has revolved around the prostate cancer indication. Specifically in patients with advanced prostate cancer.

Two randomised trials, TheraP185, 186 and VISION,187 have suggested that 177Lu-PSMA is efficacious and safe in men whose disease has progressed after treatment with enzalutamide or abiraterone and docetaxel.

Access the full publication here: https://bit.ly/3JSrCn3

In TheraP,185, 186 177Lu-PSMA was associated with a higher proportion of complete and partial responses, fewer toxic effects, and better patient-reported outcomes than cabazitaxel, whereas in VISION,187 the addition of 177Lu-PSMA to standard care was associated with increased overall survival compared with protocol-defined standard-of-care.

The lancet Commission on prostate cancer findings suggest number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040.